Home Monitoring and Molecular Phenotyping of Patients With Post-COVID With Focus on Lung Involvement

Summary

Post-acute COVID syndrome (PACS) /post-acute sequale of COVID-19 (PASC) / post-COVID is a novel clinical syndrome with unknown biological mechanisms, and to date no standard-of-care, routines for follow-up, or evidence-based treatments have been established. In this project, we will employ a systems medicine approach to identify pathways and networks of genes, proteins and metabolites that are critical in disease onset and progression, towards the goal of understanding specific mechanisms in the etiology of PASC.

The objective of the project is to perform clinical and molecular characterization and sub-phenotyping of patients with PASC, (a.k.a. PACS, or post-COVID), into mechanistically relevant groups, with focus on sex differences in patients with lung involvement. Molecular pathways involved in disease etiology will be identified by correlating rigorous clinical phenotyping and longitudinal eHealth data (home-monitoring via App, home spirometer etc), with multi-molecular level omics profiling of samples collected from the lung, integrated with our systems medicine framework. Aim I involves longitudinal home-monitoring at baseline to investigate fluctuations in general wellbeing, and causes thereof, in PASC patients with lung involvement compared to healthy controls. In Aim II, a set of omics technologies will be employed to provide in-depth molecular characterization of samples from the lung, exhaled particles (PExA), blood and urine. In depth clinical characterizations including photon-counting CT will be performed. In Aim III, integrative statistical- and network modeling approaches will be utilized to: i) identify molecularly distinct sub-groups of obstructive lung diseases based on multi-molecular level network-integration, and ii) identify individual mediators and molecular pathways related to clinical phenotype including longitudinal home-monitoring data, prognosis, diagnosis, and disease etiology of the identified sub-groups.

Conditions

• Long COVID

Sponsors & Collaborators

• Michael Runold (Clinical lead), MD, PhD

  collaborator UNKNOWN

• Kristina Piontkovskaya, MD, PhD

  collaborator UNKNOWN

• Björn Nordlund, RN, PhD

  collaborator UNKNOWN

• Angelica Lindén Hirschberg, MD, PhD

  collaborator UNKNOWN

• Tobias Granberg, MD, PhD

  collaborator UNKNOWN

• Karolinska University Hospital

  collaborator OTHER

• Swedish Heart Lung Foundation

  collaborator OTHER

• The Swedish Research Council

  collaborator OTHER_GOV

• AsthmaTuner AB

  collaborator UNKNOWN

• Karolinska Institutet

  lead OTHER

Principal Investigators

• Asa M. Wheelock, PhD · Karolinska Institutet

Eligibility

Min Age

18 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-11-21

Primary Completion

2027-12-31

Completion

2037-12-31

Countries

• Sweden

Study Locations